Top

World Journal of Urology

Published in:

01-11-2017 | Original Article

The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis

Authors: Jue Wang, Xiaobei Zhang, Tiande Zhang, Jianjun Mu, Bing Bai, Yi Lei

Published in: World Journal of Urology | Issue 11/2017

Abstract

Purpose

Ureteral stenting is associated with various morbidity and reduced quality of life. We systematically evaluated the efficacy and safety of solifenacin as monotherapy, or combined therapy with tamsulosin versus control or tamsulosin monotherapy in stent-related symptoms (SRSs).

Materials and methods

Randomized controlled trials evaluating solifenacin or its combination with tamsulosin for the treatment of SRSs were identified via a comprehensive search of Pubmed, Embase, Ovid, The Cochrane Library and relevant sources up to February 2017. Ureteral stent symptom questionnaire (USSQ) and drug-related complications were pooled for meta-analysis. Mean difference and risk difference were calculated as appropriate for each outcome to determine the cumulative effect size.

Results

There were 10 studies involving 1786 participants finally eligible in the quantitative analysis. Solifenacin monotherapy significantly reduced the total score of USSQ [MD −14.90; 95% CI (−25.19, −4.60); P = 0.005], as well as indexes of urinary symptoms, body pain, general health, sexual performance, and hematuria (P = 0.02, P = 0.009, P = 0.004, P = 0.02, P = 0.02, respectively), but the differences were insignificant when compared with tamsulosin except improved sexual performance (P = 0.004). Combined therapy of solifenacin and tamsulosin showed no beneficial effects in all indexes of USSQ over solifenacin monotherapy. Only slightly higher incidence of dry mouth (P = 0.02) was found with solifenacin versus control.

Conclusions

The result demonstrates the safety and efficacy of solifenacin in reducing SRSs, but no significant advantage was found over tamsulosin. In addition, combination of solifenacin and tamsulosin did not show beneficial effects over solifenacin monotherapy. More high quality trials are warranted to further address this issue, however.

Available only for authorised users

Zimskind PD, Fetter TR, Wilkerson JL (1967) Clinical use of long-term indwelling silicone rubber ureteral splints inserted cystoscopically. J Urol 97:840–844CrossRefPubMed

Hepperlen TW, Mardis HK, Kammandel H (1978) Self-retained internal ureteral stents: a new approach. J Urol 119:731–734CrossRefPubMed

Fiuk J, Bao Y, Calleary JG, Schwartz BF, Denstedt JD (2015) The use of internal stents in chronic ureteral obstruction. J Urol 193:1092–1100CrossRefPubMed

Pais VM Jr, Smith RE, Stedina EA, Rissman CM (2016) Does omission of ureteral stents increase risk of unplanned return visit? A systematic review and meta-analysis. J Urol 196:1458–1466CrossRefPubMed

Joshi HB, Okeke A, Newns N, Keeley FX Jr, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59:511–516CrossRefPubMed

Joshi HB, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG, Barry MJ (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069CrossRefPubMed

Staubli SE, Mordasini L, Engeler DS, Sauter R, Schmid HP, Abt D (2016) Economic aspects of morbidity caused by ureteral stents. Urol Int 97:91–97CrossRefPubMed

Damiano R, Autorino R, De Sio M, Sacco R, D’Armiento M (2005) Does the size of ureteral stent impact urinary symptoms and quality of life? A prospective randomized study. Eur Urol 48:673–678CrossRefPubMed

Betschart P, Zumstein V, Piller A, Schmid HP, Abt D (2017) Prevention and treatment of symptoms associated with indwelling ureteral stents: a systematic review. Int J Urol. doi:10.1111/iju.13311 PubMed

10.

Dellis A, Joshi HB, Timoney AG, Keeley FX Jr (2010) Relief of stent related symptoms: review of engineering and pharmacological solutions. J Urol 184:1267–1272CrossRefPubMed

11.

Lamb AD, Vowler SL, Johnston R, Dunn N, Wiseman OJ (2011) Meta-analysis showing the beneficial effect of α-blockers on ureteric stent discomfort. BJU Int 108:1894–1902CrossRefPubMed

12.

Liberati A, Altman DG, Tetzlaff J et al (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 339:b2700CrossRefPubMedPubMedCentral

13.

Shea Beverley J, Grimshaw Jeremy M, Wells George A et al (2007) Development of AMSTAR: a measurement tool to assess the methodological quality of systematic reviews. BMC Med Res Methodol 2007(15):10CrossRef

14.

Higgins JP, Altman DG, Gøtzsche PC et al (2011) The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 343:d5928CrossRefPubMedPubMedCentral

15.

Lee YJ, Huang KH, Yang HJ, Chang HC, Chen J, Yang TK (2013) Solifenacin improves double-J stent-related symptoms in both genders following uncomplicated ureteroscopic lithotripsy. Urolithiasis 41:247–252CrossRefPubMed

16.

Shalaby E, Ahmed AF, Maarouf A, Yahia I, Ali M, Ghobish A (2013) Randomized controlled trial to compare the safety and efficacy of tamsulosin, solifenacin, and combination of both in treatment of double-J stent-related lower urinary symptoms. Adv Urol 2013:752382CrossRefPubMedPubMedCentral

17.

Park J, Yoo C, Han DH, Shin DW (2015) A critical assessment of the effects of tamsulosin and solifenacin as monotherapies and as a combination therapy for the treatment of ureteral stent related symptoms: a 2 × 2 factorial randomized trial. World J Urol 33:1833–1840CrossRefPubMed

18.

Abdelaal AM, Al-Adl AM, Abdelbaki SA, Al Azab MM, Al Gamal KA (2016) Efficacy and safety of tamsulosin oral-controlled absorption system, solifenacin, and combined therapy for the management of ureteric stent-related symptoms. Arab J Urol 14:115–122CrossRefPubMedPubMedCentral

19.

Liu Q, Liao B, Zhang R, Jin T, Zhou L, Luo D, Liu J, Li H, Wang K (2016) Combination therapy only shows short-term superiority over monotherapy on ureteral stent-related symptoms—outcome from a randomized controlled trial. BMC Urol 16:66CrossRefPubMedPubMedCentral

20.

El-Nahas AR, Tharwat M, Elsaadany M, Mosbah A, Gaballah MA (2016) A randomized controlled trial comparing alpha blocker (tamsulosin) and anticholinergic (solifenacin) in treatment of ureteral stent-related symptoms. World J Urol 34:963–968CrossRefPubMed

21.

Hekal IA (2016) Drug treatment of bothersome lower urinary tract symptoms after ureteric JJ-stent insertion: a contemporary, comparative, prospective, randomised placebo-controlled study, single-centre experience. Arab J Urol 14:262–268CrossRefPubMedPubMedCentral

22.

Dellis AE, Papatsoris AG, Keeley FX Jr, Bamias A, Deliveliotis C, Skolarikos AA (2017) Tamsulosin, solifenacin, and their combination for the treatment of stent-related symptoms: a randomized controlled study. J Endourol 31:100–109CrossRefPubMed

23.

Abdelhamid MH, Zayed AS, Ghoneima WE, Elmarakbi AA, El Sheemy MS, Aref A, Abdelbary A, Nour HH (2017) Randomized, double-blind, placebo-controlled trial to compare solifenacin versus trospiumchloride in the relief of double-J stent-related symptoms. World J Urol. doi:10.1007/s00345-016-1988-y PubMed

24.

Ragab M, Soliman MG, Tawfik A, Abdel Raheem A, El-Tatawy H, Abo Farha M, Magdy M, Elashry O (2017) The role of pregabalin in relieving ureteral stent-related symptoms: a randomized controlled clinical trial. Int Urol Nephrol. doi:10.1007/s11255-017-1561-7 PubMed

25.

Koprowski C, Kim C, Modi PK, Elsamra SE (2016) Ureteral stent-associated pain: a review. J Endourol 30:744–753CrossRefPubMed

26.

Joshi HB, Newns N, Stainthorpe A, MacDonagh RP, Keeley FX Jr, Timoney AG (2003) Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure. J Urol 169:1060–1064CrossRefPubMed

27.

Yakoubi R, Lemdani M, Monga M, Villers A, Koenig P (2011) Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 186:928–934CrossRefPubMed

28.

Tanidir Y, Mangir N, Sahan A, Sulukaya M (2016) Turkish version of the ureteral stent symptoms questionnaire: linguistic and psychometric validation. World J Urol. doi:10.1007/s00345-016-1958-4 PubMed

29.

Lim KT, Kim YT, Lee TY, Park SY (2011) Effects of tamsulosin, solifenacin, and combination therapy for the treatment of ureteral stent related discomforts. Korean J Urol 52:485–488CrossRefPubMedPubMedCentral

30.

Zhou L, Cai X, Li H, Wang KJ (2015) Effects of α-blockers, antimuscarinics, or combination therapy in relieving ureteral stent-related symptoms: a meta-analysis. J Endourol 29:650–656CrossRefPubMedPubMedCentral

31.

Cardozo Linda, Heßdörfer Elke, Milani Rodolfo et al (2008) Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial. BJU Int 102:1120–1127CrossRefPubMed

32.

Gallagher EJ, Liebman M, Bijur PE (2001) Prospective validation of clinically important changes in pain severity measured on a visual analog scale. Ann Emerg Med 38:633–638CrossRefPubMed

33.

Chapple CR, Rechberger T, Al-Shukri S et al (2004) Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93:303–310CrossRefPubMed

34.

Giannarini G, Keeley FX Jr, Valent F, Manassero F, Mogorovich A, Autorino R, Selli C (2011) Predictors of morbidity in patients with indwelling ureteric stents: results of a prospective study using the validated ureteric stent symptoms questionnaire. BJU Int 107:648–654CrossRefPubMed

Title: The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis
Authors: Jue Wang
Xiaobei Zhang
Tiande Zhang
Jianjun Mu
Bing Bai
Yi Lei
Publication date: 01-11-2017
Publisher: Springer Berlin Heidelberg
Published in: World Journal of Urology / Issue 11/2017
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-017-2051-3

At a glance: The STEP trials

Springer Medicine

The role of solifenacin, as monotherapy or combination with tamsulosin in ureteral stent-related symptoms: a systematic review and meta-analysis

Abstract

Purpose

Materials and methods

Results

Conclusions

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Materials and methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2017

A prospective randomized comparison of micropercutaneous nephrolithotomy (Microperc) and retrograde intrarenal surgery (RIRS) for the management of lower pole kidney stones

Laparoscopic vesico-ureteral reimplantation with Lich–Gregoir approach in children: medium term results of 159 renal units in 117 children

Role of lymph node dissection during radical nephroureterectomy for upper urinary tract urothelial cancer: multi-institutional large retrospective study JCOG1110A

Review on diagnosis and management of urolithiasis in pregnancy: an ESUT practical guide for urologists

Population-based study of grade progression in patients who harboured Gleason 3 + 3

Factors that influence lower urinary tract symptom (LUTS)-related quality of life (QoL) in a healthy population